West and Central Africa is one of the most challenging regions for Global Fund grants. A recent Office of the Inspector General (OIG) advisory review found that weak health systems and insufficient monitoring are linked to low grant execution and slow progress against the diseases.
Guinea, a West African country of about 12 million people, faces several serious challenges in implementing its Global Fund grants. Some challenges have been related to the country’s political and epidemiological contexts. Others are related to the implementation of some Global Fund policies in the country.
In preparation for the 36th Global Fund Board meeting that took place on 16 to 17 November 2016, the Africa constituencies Bureau convened from 31 October to 1 November 2016 in Kigali, Rwanda to look at critical issues brought to the attention of the board.
Selon Médecins Sans Frontières, les pays d'Afrique Occidentale et Centrale (AOC) accusent un retard dans la réponse au VIH. MSF a indiqué que la plupart des pays de la région ont des difficultés pour offrir une thérapie antirétrovirale (TAR) : 76 % de ceux qui ont besoin du TAR - cinq millions de personnes - sont encore en attente de traitement - soit trois personnes sur quatre.
According to Médecins Sans Frontières, countries in West and Central Africa are lagging behind in the response to HIV. MSF said that most of the countries in the region struggle to offer antiretroviral therapy: 76% of those who need ART – five million people – are still awaiting treatment. That’s three out of every four people. Among children, nine out of every 10 children who need ARVs don’t have access.
Among second batch of regional concept notes, a community approach to treatment access in West Africa
While the world celebrates the recently announced achievement of 15.8 million people on antiretroviral therapy, this progress has not been evenly felt. In April 2015, the International Treatment Preparedness Coalition – West Africa (ITPC-WA) submitted an expression of interest for a regional concept note which seeks to address disproportionally low treatment access in West Africa (Figure 1).